Earl F. Ellis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Earl F. Ellis has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Andrea Kleindienst
Department of Neurosurgery, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
1 shared publicationChristian Müller
Institute of Laboratory Medicine and Pathobiochemistry, Charite, Humboldt University, Berlin, Germany
1 shared publicationJudith K. Muir
Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
1 shared publicationKaren A. Willoughby
Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia 23298-0613, USA
1 shared publicationTao Chen
Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
1 shared publication
Latest Publications
- 2 December 2004
- Published by Wiley in Journal of Neurochemistry
- Vol. 91 (6) , 1284-1291
S100B protein is released by in vitro trauma and reduces delayed neuronal injury
S100B protein in brain is produced primarily by astrocytes, has been used as a marker for brain injury and has also been shown to be neurotrophic and neuroprotective. Using a well characterized in vitro model of brain cell trauma, we examined the potential role of exogenous S100B in preventing delayed neuronal injury. Neuronal plus glial cultures were grown on a deformable Silastic membrane and then subjected to strain (stretch) injury produced by a 50 ms displacement of the membrane. We have previously shown that this injury causes an immediate, but transient, nuclear uptake of the fluorescent dye propidium iodide by astrocytes and a 24–48 h delayed uptake by neurons. Strain injury caused immediate release of S100‐beta with further release by 24 and 48 h. Adding 10 or 100 nm S100B to injured cultures at 15 s, 6 h or 24 h after injury reduced delayed neuronal injury measured at 48 h. Exogenous S100B was present in the cultures through 48 h. These studies directly demonstrate the release and neuroprotective role of S100B after traumatic injury and that, unlike most receptor antagonists used for the treatment of trauma, S100B is neuroprotective when given at later, more therapeutically relevant time points.
- 2 December 2004
- Published by Wiley in Journal of Neurochemistry
- Vol. 91 (6) , 1284-1291
S100B protein is released by in vitro trauma and reduces delayed neuronal injury
S100B protein in brain is produced primarily by astrocytes, has been used as a marker for brain injury and has also been shown to be neurotrophic and neuroprotective. Using a well characterized in vitro model of brain cell trauma, we examined the potential role of exogenous S100B in preventing delayed neuronal injury. Neuronal plus glial cultures were grown on a deformable Silastic membrane and then subjected to strain (stretch) injury produced by a 50 ms displacement of the membrane. We have previously shown that this injury causes an immediate, but transient, nuclear uptake of the fluorescent dye propidium iodide by astrocytes and a 24–48 h delayed uptake by neurons. Strain injury caused immediate release of S100‐beta with further release by 24 and 48 h. Adding 10 or 100 nm S100B to injured cultures at 15 s, 6 h or 24 h after injury reduced delayed neuronal injury measured at 48 h. Exogenous S100B was present in the cultures through 48 h. These studies directly demonstrate the release and neuroprotective role of S100B after traumatic injury and that, unlike most receptor antagonists used for the treatment of trauma, S100B is neuroprotective when given at later, more therapeutically relevant time points.